newsfilter
← Latest News
GlobeNewswire·

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

TELO
  • Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing Telomir-Zn suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models.
  • The manuscript titled "Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer" appeared in the Journal of Oncology Research and Therapy.
  • Telomir-Zn targets KDM enzymes by depleting the intracellular iron required for their catalytic activity.
  • Iron-rescue experiments confirmed the compound's anti-cancer effects depend specifically on iron depletion rather than general toxicity.
  • The drug demonstrated selectivity by killing TNBC cells at low concentrations while leaving normal cells unharmed at concentrations over 50-fold higher.
  • Oral Telomir-Zn suppressed tumor growth in prostate models and reactivated silenced tumor-suppressor genes including STAT1, GSTP1, RASSF1A, CDKN2A, and MASPIN.
  • In TNBC xenografts, the compound reduced primary tumor size and significantly decreased metastatic dissemination in HCC1806 models.
  • Combination therapy with paclitaxel produced greater tumor reduction than either agent alone in BT-549 xenografts, though MDA-MB-231 models showed no response due to heterogeneous sensitivity.
  • The findings support advancing Telomir-Zn into a planned Phase 1/2 clinical trial for patients with advanced or metastatic TNBC under an active IND.
  • Management stated the approach addresses a fundamental vulnerability in TNBC by targeting upstream metabolic drivers of epigenetic silencing rather than downstream consequences.